Identification of treatment-experienced hepatitis C patients with poor
cost-effectiveness of pegylated interferon plus ribavirin from a real-world
cohort.
Liu TW, Tsai PC, Huang CI,
et
al
J Formos Med Assoc. 2017
Apr 4
Abstract
Treatment of HCV in renal transplant patients with
peginterferon and ribavirin: long-term follow-up.
Mak SK, Sin HK, Lo KY,
Clin Exp Nephrol.
2017 Jan 12.
Abstract
A nationwide survey of specialist knowledge on current standard of care
(Peg-IFN/RBV) and barriers of care in chronic hepatitis C patients in China.
Wei L, Li J, Yang X, Wang G, et al
J Gastroenterol Hepatol.
2016 Apr 4.
Abstract
FULL-TEXT ARTICLE
Regional differences in hepatitis C treatment with peginterferon and
ribavirin in Japan: a retrospective cohort study.
Ide
K, Kawasaki Y, Yamada H, Masaki N.
Drug Des Devel Ther.
2016 Mar 22;10:1217-23.
Paper
FULL-TEXT ARTICLE
Ribavirin Concentrations Do Not Predict Sustained Virological Response in
HIV/HCV-Coinfected Patients Treated with Ribavirin and Pegylated Interferon
in the Swiss HIV Cohort Study.
Kovari H, Russmann S, Ledergerber B, et
al
PLoS One. 2015 Jul
28;10(7):e0133879.
Paper
Sustained virologic response to standard interferon or
pegylated interferon and ribavirin in patients with hepatitis C virus
genotype 5: systematic review and meta-analysis of ten studies and 423
patients.
Devaki P, Jencks D, Yee BE, Nguyen MH.
Hepatol Int. 2015 May
28.
Abstract
Efficacy of pegylated interferon and ribavirin combination
therapy for patients with hepatitis C virus infection after curative
resection or ablation for hepatocellular carcinoma-A retrospective
multicenter study.
Harada N, Hiramatsu N, Oze T,
et al
J Med Virol. 2015 Mar 13.
Abstract
Effect of Aging, Glucose Level, and HIV Viral Load on
Response to Treatment with Pegylated Interferon Plus Ribavirin in HIV/HCV
Co-Infected Women.
Nasta P, Maida I, Cattelan AM, et al
J Womens Health (Larchmt).
2015 Feb;24(2):159-64
Abstract
Peg-IFN and ribavirin treatment for recurrence of genotype 2 and
3 hepatitis C after liver transplantation.
Ackefors M, Castedal M,
Dahlgard O, et al
Infect Dis (Lond). 2015 Feb 4:1-9.
Abstract
Patterns of longitudinal change in hepatitis C virus neutralization titers
correlate with the outcome of peginterferon and ribavirin combination
therapy.
Lin J, Wang W, Xu Y, et al
J Med Virol. 2015 Feb 4.
Abstract
Meta-analysis: influence of host and viral factors in patients with chronic
hepatitis C genotype 4 treated with pegylated interferon and ribavirin.
Yee BE, Nguyen NH, Zhang B, et al
Eur J Gastroenterol Hepatol. 2014
Aug 28
Abstract
Is there still a role for PEG IFN+RBV therapy in patients with HCV genotype
1?
Serfaty L.
Liver Int. 2014 Feb;34 Suppl 1:11-2. .
Abstract
Characteristics of the cellular immune response in HIV/HCV
patients with hemophilia during peginterferon/ribavirin therapy in southern
China.
Yingying L, Jiangrong W,
Jing L.
Diagn Microbiol Infect Dis. 2013 Oct 30.
Abstract
Identification
of Naďve Hcv-1 Patients with Chronic Hepatitis who may Benefit from Dual
Therapy with Peg-Interferon and Ribavirin
Andriulli A, Marco VD, Margaglione M, et
al
J Hepatol. 2013 Aug 20.
Abstract
Hepatitis C genotype 1 virus with low viral load and rapid virologic response
to peginterferon/ribavirin obviates a protease inhibitor.
Pearlman BL, Ehleben C.
Hepatology.
2013 Jul 19.
Abstract |
Peg
Interferons
Main Page
Main
New/Newsworthy
Documents identified with this icon are in Portable Document Format (PDF)
and require the
Adobe
Acrobat Reader
